Program
Valacyclovir
Also written as “Valacyclovir hydrochloride”, “Valaciclovir” and “Valacyclovir Hydrochloride”.
Its studies are mostly in Herpes Genitalis · Herpes Zoster · Herpes Simplex · Prostatic Neoplasms · Lung Neoplasms, led by 7 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| GlaxoSmithKline | 110 open or running | phase 4since Mar 18, 2004 | Nov 2, 1999 | none ahead |
| Viatris | 30 open or running | phase 1since Mar 30, 2008 | Mar 30, 2008 | none ahead |
| Dr. Reddy's Laboratories | 20 open or running | phase 1since Jun 2, 2010 | Jun 2, 2010 | none ahead |
| Hikma Pharmaceuticals | 20 open or running | no phasesince May 25, 2010 | May 25, 2010 | none ahead |
| Sun Pharmaceutical Industries | 20 open or running | no phasesince Oct 15, 2010 | Oct 15, 2010 | none ahead |
| Teva Pharmaceutical Industries | 20 open or running | phase 1since Jun 21, 2010 | Jun 21, 2010 | none ahead |
| aRigen Pharmaceuticals | 10 open or running | phase 2since Apr 1, 2008 | Apr 1, 2008 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 3 studies since Nov 2, 1999.
- May 11, 2000Phase 3 study in Herpes SimplexGlaxoSmithKline · NCT00005663 · United States, Canada
- Mar 18, 2004Phase 4 study in Herpes GenitalisGlaxoSmithKline · NCT00079911 · 7 enrolled · United States, Australia, Hong Kong
- Jun 30, 2005Phase 4 study in Herpesviridae InfectionsGlaxoSmithKline · NCT00116844 · 73 enrolled · United States
- Sep 8, 2005Phase 4 study in Herpes GenitalisGlaxoSmithKline · NCT00158860 · 384 enrolled · United States, Argentina, Brazil and more
- Sep 9, 2005Phase 3 study in ChickenpoxGlaxoSmithKline · NCT00169416 · 43 enrolled
- Feb 24, 2006Phase 1 study in Herpes SimplexGlaxoSmithKline · NCT00297206 · 36 enrolled · United States, Chile, South Africa
- Mar 21, 2006Phase 4 study in Herpes LabialisGlaxoSmithKline · NCT00306293 · 70 enrolled · United States
- Jun 21, 2006Phase 4 study in Virus DiseasesGlaxoSmithKline · NCT00343278 · 18 enrolled
- Mar 30, 2008Viatris's first studies: 3 phase 1 studies in HealthyNew to ViatrisViatris · NCT00650494, NCT00649974, NCT00649870
- Apr 1, 2008aRigen Pharmaceuticals's first study: phase 2 study in Herpes ZosterNew to aRigen PharmaceuticalsaRigen Pharmaceuticals · NCT00652184 · 300 enrolled · United States
- May 25, 2010Hikma Pharmaceuticals's first studies: 2 no phase studies in Herpes ZosterNew to Hikma PharmaceuticalsHikma Pharmaceuticals · NCT01132729, NCT01132716
- Jun 2, 2010Dr. Reddy's Laboratories's first studies: 2 phase 1 studies in HealthyNew to Dr. Reddy's LaboratoriesDr. Reddy's Laboratories · NCT01136538, NCT01136525
- Jun 21, 2010Teva Pharmaceutical Industries's first studies: 2 phase 1 studies in HealthyNew to Teva Pharmaceutical IndustriesTeva Pharmaceutical Industries · NCT01149499, NCT01149460
- Oct 15, 2010Sun Pharmaceutical Industries's first studies: 2 no phase studies in HealthyNew to Sun Pharmaceutical IndustriesSun Pharmaceutical Industries · NCT01222910, NCT01222897
TargetBeta
A vaccine: it acts on a pathogen, not a human gene.
“Human herpesvirus 1 DNA polymerase inhibitor”ChEMBL 37, by rule
Studies
All 23 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT01222910Healthy · India | – | Completed | Sun Pharmaceutical Industries | May 2009 | 36 |
| NCT01222897Healthy · India | – | Completed | Sun Pharmaceutical Industries | May 2009 | 40 |
| NCT01149499Healthy · United States | 1 | Completed | Teva Pharmaceutical Industries | Jan 2005 | 60 |
| NCT01149460Healthy · Canada | 1 | Completed | Teva Pharmaceutical Industries | Sep 2004 | 36 |
| NCT01136538Healthy · India | 1 | Completed | Dr. Reddy's Laboratories | Feb 2007 | 34 |
| NCT01136525Healthy · India | 1 | Completed | Dr. Reddy's Laboratories | Mar 2007 | 41 |
| NCT01132729Herpes Zoster · United States | – | Completed | Hikma Pharmaceuticals | Sep 2006 | 48 |
| NCT01132716Herpes Zoster · United States | – | Completed | Hikma Pharmaceuticals | Sep 2006 | 48 |
| NCT00652184Herpes Zoster · United States | 2 | UNKNOWN | aRigen Pharmaceuticals | Jun 2009 | 300 |
| NCT00650494Healthy · United States | 1 | Completed | Viatris | Aug 2005 | 66 |
| NCT00649974Healthy · United States | 1 | Completed | Viatris | May 2005 | 28 |
| NCT00649870Healthy · United States | 1 | Completed | Viatris | May 2005 | 26 |
| NCT00343278Virus Diseases | 4 | Completed | GlaxoSmithKline | Aug 2005 | 18 |
| NCT00306293Herpes Labialis · United States | 4 | Completed | GlaxoSmithKline | Nov 27, 2006 | 70 |
| NCT00297206Herpes Simplex · United States, Chile, South Africa | 1 | Completed | GlaxoSmithKline | Feb 28, 2007 | 36 |
| NCT00169416Chickenpox | 3 | Completed | GlaxoSmithKline | Aug 2005 | 43 |
| NCT00158860Herpes Genitalis · United States, Argentina, Brazil and more | 4 | Completed | GlaxoSmithKline | Jul 26, 2006 | 384 |
| NCT00116844Herpesviridae Infections · United States | 4 | Completed | GlaxoSmithKline | Jan 10, 2006 | 73 |
| NCT00079911Herpes Genitalis · United States, Australia, Hong Kong | 4 | Terminated | GlaxoSmithKline | Oct 15, 2004 | 7 |
| NCT00005663Herpes Simplex · United States, Canada | 3 | UNKNOWN | GlaxoSmithKline | ||
| NCT00002404Herpes Simplex | – | Completed | GlaxoSmithKline | 30 | |
| NCT00002084Herpes Simplex · United States | – | Completed | GlaxoSmithKline | ||
| NCT00002000Herpes Simplex · United States | – | Completed | GlaxoSmithKline |
How it is read
Names in the registry
- “Valacyclovir hydrochloride”, 6 entries
- “Valacyclovir”, 4 entries
- “Valaciclovir”, 4 entries
- “Valacyclovir Hydrochloride”, 4 entries
- “Valacyclovir Hydrochloride Tablets 1000 mg”, 2 entries
Conditions, from the studies’ own filings
- Herpes Genitalis, 4 studies
- Herpes Zoster, 4 studies
- Herpes Simplex, 4 studies
- Prostatic Neoplasms, 1 study
- Lung Neoplasms, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.